Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pifithrin is a small molecule inhibitor of the tumor suppressor protein p53 (TP53). It was originally identified for its ability to protect cells from p53-mediated apoptosis induced by DNA-damaging agents or radiation. Pifithrin-alpha, the most common analog, acts by reversibly inhibiting p53-dependent transcriptional activity and mitochondrial translocation. While widely used as a research tool to investigate p53 signaling pathways in various models, including cancer and neuroprotection, it has not reached clinical approval. In the context of oncology research, it is often used to validate the role of p53 in suppressing endogenous retroviruses or to model p53-deficient states in cell lines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pifithrin.